Given the evidence that AREG plays more important roles than EGF in the regulation of ovarian cancer progression, it is interesting and important to examine whether SPRY2 can be regulated by AREG and whether SPRY2 also affects the biological functions of AREG. Here, SPRY2 is linked to ovarian cancer.